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Beyond white light: novel optical enhancement magnification colonoscopy to 
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ABSTRACT 
Introduction: The i-scan Optical Enhancement (OE) with magnification (Pentax) is a 
recently introduced combination of optical and digital enhancement electronic virtual 
chromoendoscopy (EVC) which enhances the colonic mucosa in much higher resolution 
than white light standard endoscopy (WLE). For reference, we also recorded WLE Mayo 
endoscopic score and biopsies were scored by Robarts Histology Index (RHI) and  
histological ECAP score.
 
 
Methods:  Consecutive patients with UC undergoing the new OE-iscan –EPKi 7010 with 
magnification were enrolled for assessment of the grade of inflammation. The OE-iscan 
score was divided into mucosal and vascular pattern score as well as overall score. The 
diagnostic accuracy of OE i-scan was calculated with histology as gold standard (RHI 
and ECAP). 
 
Results: 50 consecutive patients (41 UC and 9 control) were included in the study (25 
men, median age 49y, range 24-79y). The endoscopic appearance by overall OE -iscan  
score correlated with ECAP (r=0.70;p<0.0001) and the accuracy of OE-iscan to detect 
abnormalities by ECAP was 80% (sensitivity 77.7%; specificity 100%). The correlation 
between Mayo endoscopic score and ECAP score was less strong (r=0.432; p<0.001). 
Both the OE-iscan vascular and mucosal scores correlated with ECAP score (r=0.65 and 
0.71 respectively; p<0.001). The correlation between OE-iscan score and RHI (r=0.61; 
p<0.01) and the accuracy to detect abnormalities by RHI was 68% (sensitivity 78.1% 
specificity 50%).  
Conclusion : The new OE-iscan may accurately reflect histologic abnormalities 
demonstrated by ECAP histology score which incorporates the full spectrum of acute and 
chronic histologic abnormalities.  
 
 
 
 
Keywords: Optical Enhancement, iscan, electronic virtual chromoendoscopy, mucosal 
healing, ulcerative colitis , ECAP, RHI 
 
 
 
 
 
 
 
Introduction 
 
Current white light endoscopy (WLE) based colonoscopy scores have limitations in 
defining mucosal inflammation and healing in ulcerative colitis (UC) when compared 
with histology which represents the gold standard (1,2). Endoscopic mucosal healing 
(MH) is becoming established as the main target in the treat to target ‘Strategy for 
Therapies in UC Patients’. (STRIDE) (3) However, the term endoscopic MH is 
currently empirically defined and a common question asked is ‘how deep is deep 
enough’ in MH.  A precise endoscopic and histologic assessment of inflammation and its 
degree are important in clinical practice and in clinical trials (2,9. Stratification of 
outcomes of IBD and endpoints of therapy maybe further optimized by adoption of 
advanced endoscopic techniques, which are currently not widely used in routine clinical 
practice. Electronic virtual chromoendoscopy (EVC) can provide detailed 
characterization of inflammatory changes of the intestinal mucosa and better detect subtle 
residual inflammation when compared with histology. (10-14,16) We recently developed 
an EVC scoring platform for UC that defines subtle inflammation and MH (14) by 
specifically characterizing vascular and mucosal pattern changes which correlate very 
well with the histological scores.  
 
 We report our experience on using the newly introduced i-scan Optical Enhancement 
(OE) with magnification (Pentax, Japan) in assessing inflammatory changes in UC.  
OE i-scan MagniView
TM 
(Pentax Japan) colonoscopes offer the latest generation of 
dyeless chromoendoscopy with magnification. (17) This is a unique combination of 
optical and a digital  enhancement chromoendoscopy in a single system which offers the 
endoscopists better detection and detailed characterization of inflammation and 
associated neoplastic changes. The system consists of three types of algorithms: OE for 
blood vessel,  glandular ducts and mucosal characterization , Surface Enhancement i-scan 
1 (SE) for detection of abnormalities in the gastrointestinal tract and Tone Enhancement 
i-scan 2 (TE) for pattern characterization.   Each of these algorithms can be selected by 
pressing a pre-assigned button on the hand-piece of the scope (11,17). The newly added 
OE employs band-limited light to achieve  higher overall transmittance by connecting the 
peaks of the hemoglobin absorption spectrum (415,540 and 570 nm ), thus creating a 
continuous wavelength spectrum. This new system is similar to narrow band 
imaging(NBI) but with better illumination and brightness by overcoming the spectral 
distribution and darkness of NBI especially in the areas with a large lumen such as the 
colon. The optical zoom with magnification further assist in the early detection, 
characterisation and demarcation by enhancing the images by a minimum of 136 times. 
 
The aims of this study are to assess whether OE-i-scan MagniView 
TM 
(Pentax) has the 
potential to characterize and define more accurately subtle inflammation and endoscopic 
MH in UC patients compared with histological inflammation. We also aimed to develop a 
new redefined virtual OE-iscan Magniview
TM
 mucosal and vascular score that can be 
more precise to assess changes in UC and reflect histology. We also aimed to compare the 
score using the new virtual OE-i-scan MagniView TM with existing endoscopic and 
histological scores. 
 
 
PATIENTS AND METHODS 
 
This was a prospective cohort study performed at a single tertiary referral centre and the 
Calgary Conjoint Health Services Research Ethics Board of the University of Calgary 
(CHREB) approved it. Patients with UC referred for surveillance colonoscopy or for 
assessment of disease activity were enrolled in the study after they provided informed 
consent. Patients with UC were eligible for the study when they had indication for 
surveillance colonoscopy, for disease activity assessment or for assessing response to 
treatment. Patients were excluded when they were pregnant, toxic megacolon or unable to 
provide informed consent. All patients had OE-iscan colonoscopy with magnification and 
histology and were assessed by MI, SG and XG respectively.  
 
PATIENTS 
Forty-one consecutive patients with inactive or active UC and 9 controls who underwent 
screening colonoscopy for colonic polyps detection (32 men, median age 49y, range 24-
79) during the period from August 2015 to April 2016, were analyzed for assessment of 
inflammatory activity and MH using the new OE-iscan and MagniView colonoscopy 
(EPKi 7010, EC-3890LZi, Pentax, Japan). The extent of UC was described according to 
the Montreal classification (18) Clinical disease activity was determined using the Mayo 
clinical disease activity score ranging from 0-12 (19). The patient demographics, 
medication use and CRP concentrations at the time of colonoscopy were also recorded 
and are shown in table 1.  
 
ASSESSMENT with OE-iscan MagniView 
TM
   
 
After preparation by 4 litres of polyethylene glycol electrolyte lavage solution, patients 
underwent colonoscopic assessment. Colonoscopies were performed by one IBD 
colonoscopist (MI) experienced in novel endoscopic images. The procedures were 
scheduled as normal colonoscopic practice. The assessment of the OE i-scan with 
magnification endoscopic images and videos were done by 2 endoscopists (MI, SG) and 
the inter-observer agreement was calculated (Kappa agreement statistics). 
 
All patients were initially assessed by using Mayo Endoscopic score (0-3) (19) with high 
definition WL endoscopy (WLE). After that, the three algorithms settings consisted of 
Surface enhancement i-scan1 for detection of inflammation, tone enhancement i-scan 2 
for mucosal and vascular characterization and OE for vessel and detailed assessment of 
patchy inflammation and MH with and without magnification. (Table3). In the Mayo 
endoscopic score, mucosal pattern and vascular pattern are not well distinguished from 
each other. We have previously described that HD i-scan colonoscopy can better 
characterize vascular patterns clearly and therefore the description of loss of vascular 
pattern or obliterated in UC by Mayo and UCEIS endoscopic score has been replaced by 
more detailed description of the abnormalities of vascular pattern such as isolated spiral 
drop-out vessels by using EVC. We also described and redefined the abnormal mucosal 
pattern separately under i-scan(15). In the UCEIS system the mucosal pattern was 
described separately but mainly based on erosions and ulcers. (20).  
 
The new modified OE-iscan virtual chromoendoscopy score was developed  based on the 
our iscan score  previously described in our manuscript. (15). The new modified score 
included all the spectrum of acute and chronic mucosal and vascular changes  with more 
detailed definition of MH . We based our assessment on the framework of our previous i-
scan score which recently has been modified for mucosal inflammation that specifically 
characterizes vascular and mucosal changes which correlate very well with histological 
scoring systems such as Harpaz and ECAP designed by Gui (15),  
The mucosal pattern was graded according to subtle changes of crypt architecture, to 
micro-erosions to erosions and then ulceration. The vascular pattern changes were graded 
according to the subtle vascular architecture changes to intra-mucosal bleeding and to 
frank luminal bleeding. The assessment was done during insertion of the colonoscope.  
 
Mucosal pattern was graded :  
1. Normal – Mucosa Healing :  roundish/dilated /absent crypts 
  
2. Mild inflammation : roundish crypts with microerosions 
  
3. Moderate inflammation : mosaic –elongated crypts with erosions 
  
4. Severe Inflammation : crypt necrosis with hyperplasia of crypts and  ulcers   
 
The vascular pattern was graded : 
1.  Normal –Vascular Healing: roundish surrounding the crypts /vessels drop-out or 
isolated spiral vessels  
  
2. Mild Inflammation : roundish /crowded –tortuous vessels  
 
3. Moderate inflammation : Dilated vessels with intra-mucosal bleeding 
  
4. Severe inflammation : vessels destruction with spontaneous luminal bleeding  (Fig1-
3) 
 
HISTOLOGIC ASSESSMENT 
The mucosal biopsies were taken from the same regions assessed by OE i-scan with 
magnification. A comprehensive and more detailed histological review which reflected 
all the chronic and acute changes of inflammation was independently performed by a 
single gastrointestinal histopathologist (XG) who was blinded to the endoscopic findings. 
This scoring (ECAP system – Extent, Chronicity, Activity, Plus additional findings) 
system was previous designed independently by XG alongside the i-scan score to assess 
all even minimal chronic mucosal changes in UC (14). The details of the system are 
shown in Table 4.  
 
Two other IBD histological grading scheme were used; NYMS (New York Mount Sinai 
system) developed by Harpaz (21), and the new recently validated Robarts histological 
index (RHI) were used for comparison (22) with endoscopy.  These scores designed for 
clinical trials but also currently used sometimes in clinical practice, focuses on the 
activity of colitis, as shown in Table 4   
 
STATISTICAL ANALYSIS 
The parametric data are expressed as the mean and SD and categorical data as 
percentages. Sensitivity Specificity, Accuracy, PPV and NPV of OE-iscan to detect 
abnormalities by ECAP and RHI were calculated.   Correlation between Mayo 
endoscopic scores , the new redefined OE-i-scan  and histological scores used were 
calculated by the non-parametric Spearman correlation coefficient. The correlation 
coefficients were used to indicate the linear relationship between different methods but 
these do not indicate agreement.  
The two endoscopist analyzed at least 4 high quality images alongside with a video clip 
of 60-90 seconds in duration from each patient enrolled and Cohen Kappa statistics were 
calculated. The images and the videos were anonymous. The inter-observer agreement 
was calculated .Interpretation of k values was done according to evaluation of Cohen’s k 
with > 0.75 indicating good agreement, 0.4-0.75 fair to good agreement, and <0.4 poor 
agreement.  
 
Results  
Patient details 
The extent of UC according to the Montreal classification [16] was as follows:  21/41 
(51.2%) patients had left sided UC (E2), 20/41 (48.8%) patients had ulcerative pancolitis 
(E3).  Mayo endoscopic subscore were 0 in 22/41 (53.6%) patients, 1 in 7/41 (17%) 
patients,  2 in 8/41 (19.5%) patients and 3 in 4/41  (9.7%) patients. (Table 1).  
 
 
 Endoscopic assessment  
Relationship between OE-iSCAN and histology in UC 
OE-i-scan mucosal pattern grade 1 (normal or MH) was seen in 11/41 (26.8%) patients, 
grade 2 (mosaic pattern and micro-erosions) was seen in 16//41 (39%) patients, grade 3 
(erosions) was seen in 10/41 (24.4%) patients and grade 4 (elongated/necrotic crypts with 
ulcers) in 4/41(9.7%) patients. OE-iscan vascular pattern grade 1 (roundish, drop-out or 
isolated vessels) was seen in 8/41(19.5%) patients, grade 2 (roundish/crowded tortuous) 
was seen in 17/41 (41.4%) patients, grade 3 (intra-mucosal bleeding and dilated vessels) 
was seen in 12/41 (29.2%) patients and grade 4 (luminal spontaneous bleeding) was seen 
in 4/41 (9.7%) patients. (Table 2) 
The endoscopic appearance by overall OE-iscan score correlated with ECAP (r=0.70; 
95%CI: 0.52-0.81; p<0.0001). Both the OE-iscan vascular and mucosal scores correlated 
with ECAP score (r=0.65; 95%CI: 0.45-0.78; and 0.71; 95%CI:0.54- 0.82 respectively; 
p<0.001).(Table 5).The accuracy, sensitivity, specificity, PPV, and NPV and of OE-
iSCAN to assess inflammation and mucosal healing in UC by ECAP  were 
80%,78%,100%,100%(95%CI:90-100%),33.3%(95%CI:15.1-58.2%), respectively while 
the correlation between OE-iSCAN score and RHI was significant (r=0.61; p<0.01). The   
accuracy, sensitivity, specificity, PPV, NPV of OE-iSCAN to detect abnormalities by 
RHI were 68% 78%, 50%, 73.5%(95% CI: 56.8-85.3) 56.2%(95%CI: 33.1-76.9), 
respectively. (Table 5) 
The RHI unlike ECAP only scores acute but not chronic histological changes. The 
NYMS [20] was also used for comparison. This system, which is currently used in 
clinical practice, focuses mostly on the activity of colitis (Table 4) 
Relationship between WL (Mayo endoscopic score) with   OE-iSCAN and  histology 
in UC 
The overall OE-i-scan scores (mucosal and vascular pattern) were also significantly 
correlated with Mayo endoscopic score (rs =0.74; 95% CI: 0.58-0.84; p < 0.0001). The 
accuracy, sensitivity, specificity, PPV and NPV by Mayo were 62%, 47%, 94%, 94.1%, 
(95% CI: 73-99), 45.4% (95% CI: 30-62). 
The correlation between Mayo endoscopic score and ECAP score was less strong than 
that between OE i-scan and ECAP scores (r=0.42; 95% CI: (0.17-0.63) p<0.001). The 
accuracy, sensitivity, specificity, PPV and NPV of Mayo score to assess abnormalities in 
UC patients by ECAP were 36%, 36% ,NaN, 100 (CI 95%: 82.4-100), 0 (CI 95%: 0-
10.7).  
The correlation between Mayo endoscopic score and RHI score was also low (r=0.49; 
95% CI :(0.24-0.67); p<0.001). The accuracy, sensitivity, specificity, PPV and NPV of 
Mayo to evaluate inflammation by RHI were 54%, 37.5%, 83.3%, 80 (CI 95: 55-93) 
62.8% (CI: 95%: 28-59) (Table 5-6) 
 
  Of 41 patients with UC, 23 (54.7%) patients had a Mayo endoscopic subscore of 0. Of 
those with Mayo endoscopic subscore of 0, 10 of them (23.8%) had an abnormal mucosal 
pattern and 7 (16.6%) of them had an abnormal vascular pattern on OE i-scan 
MagniView 
TM 
colonoscopy as shown in Table 2.  
 
The inter-observer agreement of the OE iSCAN scores was calculated and the k statistic 
was 0.79 (95% CI 0.67- 0.88) and the strength of observation was considered to be 
‘good’. 
 
Discussion  
We have demonstrated that OE i-scan assessment of mucosal inflammation and healing 
correlated with histologic scores better that the Mayo endoscopy scores. In addition, OE 
i-scan detected subtle inflammatory changes by picking up abnormal mucosal or vascular 
pattern in approximately a quarter of the patients. The Mayo endoscopy score correlated 
with RHI or ECAP scores less strongly than the OE-iSCAN score; the RHI represents 
mainly the acute therapy responsive features of histology in UC while the ECAP 
represents the full spectrum of histology changes, both acute and chronic. This would 
support the concept that OE i-scan assessment of the inflammation in UC approximates 
to histologic changes better than the Mayo endoscopy score, and further demonstrates 
that EVC, by virtue of assessment of fine mucosal and vascular changes, has the capacity 
of detecting more of the subtle inflammatory changes as demonstrated by histology. (15) 
 
The clinical implications of assessment of subtle inflammatory changes in UC remain 
controversial. A recent study has suggested that histologic abnormalities reflect clinical 
outcomes better than existing endoscopy scores (23). Other retrospective cohort studies 
have suggested that patients with Mayo subscore 0 have lower colectomy rates than 
patients with Mayo subscore 1. In patients who were in clinical remission on 5-
aminosalicylic acid, doubling the dose of the drug could further reduce fecal calprotectin 
(24). However, pivotal clinical trials in ulcerative colitis using anti-TNF drugs showed 
that colectomy rates in patients who achieved Mayo endoscopy score of 0 or 1 at week 8 
after commencement of therapy had similar colectomy rates at week 52 (25).  
 
Some of the traditional endoscopic features of UC are based on WLE endoscopy and 
indeed may date back to endoscopes that provided less details of mucosal and vascular 
architecture. Loss of vascular pattern, a classic feature of UC, is no longer a feature with 
EVC assessment, as abnormal vascular pattern rather than complete loss of it is now 
appreciated. Friability has always been problematic in assessment of the UC affected 
mucosa as this dates back to the days of rigid sigmoidoscopy. (19) With EVC, abnormal 
vascular patterns are readily recognized, and intramucosal bleeding can be distinguished 
from luminal bleeding, reflecting increasing severity of inflammation, and refining 
identification of ‘friability’. Some of the newer endoscopic scores such as UCEIS and 
UCCIS have tried to address some of these drawbacks, but these scores also reflect WLE  
endoscopic appearances, rather than HD resolution with added electronic filter techniques 
and magnification. These latter scopes are permitting use of a new language around 
endoscopic abnormalities in UC, including crypt architecture, recognition of micro-
erosions, and fine vascular changes around the crypts. (15,26,27) 
 
Histologic changes, both acute and chronic may map to outcomes such as relapses, 
colectomy as well as risk of dysplasia. There is a clear relationship between the grade and 
chronicity of inflammation in the colon and the risk of colorectal cancer. Better control of 
inflammation demonstrated with MH, may be associated with a decreased risk of cancer 
[27,28, 29].  Therefore endoscopic assessment that reflects the entire spectrum of 
histologic chronic and acute changes as represented by ECAP may permit future 
longitudinal prospective studies to determine the clinical meaningfulness of the ability to 
detect subtle changes. In addition, as the Mayo endoscopy score is a four point score 
(each point reflecting multiple features), its operational characteristics are limited and 
may not capture the entire range of inflammatory changes. 
 
The latest OE i-scan MagniView
TM
 is a combination of digital and optical enhancements, 
the existing i-scan and the new OE, which together can bring additional and more 
detailed information, especially in the mucosal vascularization pattern to accurately 
perform almost in vivo diagnosis based on crypt architecture and fine vessel patterns. 
(17) We have showed accuracy of OE-iscan to be 80 % to assess abnormalities by ECAP, 
which reflected acute and subtle chronic histological changes in UC (15). Kodashima  et 
al have first showed that OE improves endoscopic detection and characterization of 
esophageal SCC compared with WLE. (30) Robles-Mendranda et al have presented their 
first experience to assess minimal esophageal inflammatory changes in the GERD 
patients using the OE system with Magniview. (31) They have showed that the new 
endoscopic system can predict gastroesophageal reflux disease with high sensitivity and 
accuracy. Neumann et al have shown  that OE-iscan improve polyps characterization 
.(32)  We have also demonstrated that gastroenterologists and physicians without prior 
experience in novel i-scan OE magnification colonoscopy achieved significant 
improvement in predicting polyps histology after a brief training session using videos. 
(33) 
 
This is the first study exploring the use of OE i-scan technology in assessing UC. Our 
study was aimed at investigating whether subtle inflammation can be detected 
endoscopically, when Mayo endoscopy score is 0, which is the case with histologic 
changes. In pivotal clinical trials both Mayo endoscopy score of 0 or 1 are denoted as 
mucosal healing, which may be an over-simplication relative to histological changes. 
Our study has limitations – the scoring system will need to be validated but this will 
require more familiarity of endoscopists first with the OE-iscan technology before 
conducting a validation study. Our observations of abnormalities detected by OE i-
scan may help in this process of future studies. Our study had single operator, but as 
availability of the OE i-scan technology widens, multi-operator studies will need to 
be performed. Furthermore, the  good inter-observer variability between two 
experienced endoscopists in i-scan that have assessed pictures and videos clips 
gives robustness to the OE-iscan score in addition to the good correlation with the 
existing and partially  validated endoscopic and histological scores.  
 
The responsiveness of our score to therapeutic interventions will require to be 
determined and short and medium term consequences of persistent subtle 
inflammation in patients who are in clinical and endoscopic remission by WLE. 
 
In conclusion, advancing endoscopic technology is now promising to give us mucosal 
details at almost histological levels, capturing both acute and chronic changes and using 
scopes that can be incorporated in clinical practice.  
However, these new endoscopic scores need to be validated and standardized in 
multicenter international prospective studies.  
 
 
 
Legends to figures: 
 
 Figure 1: OE-iscan with magnification showed a) the opening dilated crypts of the 
mucosal healing UC appearance b) a tiny micro erosion with dilated vessels surrounding 
the  opening of the crypts c) microerosions vs erosions d) size  of the ulcer  
 
Figure 2: OE-iscan with magnification showed a) crytps necrosis b) dilated vessels 
surrounding the opening of the crypts c) intramucosal  bleeding  d) luminal bleeding  
 
Figure 3. OE-iscan with magnification showed a-b) patchy inflammation with dilated 
vessels surrounding the crypts and alternate areas of MH with by spiral isolated vessels; 
Histological section  (Hematoxylin & Eosin, magnification × 200.) minimally active 
chronic colitis c-d) MH vascular pattern with spiral isolated vessels; Histological section  
(Hematoxylin & Eosin, magnification × 200) quiescient  chronic UC 
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Tables 
 
Table 1. Baseline characteristics of Enrolled Cohort  
(n= 41 UC and 9 controls) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical data 
 
Patients 
Age, median (range) years 49 (24-79) 
Male n (%) 32 (64) 
Disease duration (mean± SD range, 
years) 
 
17.1 ± 11.7 (1-47) 
Extension n (%)  
Proctitis 0 (0) 
Pancolitis 21 (51.2) 
Left-sided 20 (48.8) 
 
Mayo endoscopic score n (%) 
 
0 22 (53.7) 
1 7 (17.1) 
2 8 (19.5) 
3 4 (9.8) 
 
Current medication n (%) 
 
None 2 (4.9) 
Mesalamine 21 (51.2) 
Azathioprine/Methotrexate 3 (7.3) 
Anti-TNF 5 (12.2) 
Combination treatment 10 (24.4) 
Steroids 0 (0) 
 
Laboratory Markers mean ± SD 
 
CRP, mg/L 5.3 ± 11.3 
  
  
 
 
 
 
 
 
 
Table 2   Assigned scores:  Mayo Endoscopic score (WLE) and OE-iscan mucosal and 
vascular pattern 
 
 
 
 
 
 
Table 3.  The OE-iscan modes settings used in this study to assess and characterize 
inflammation and mucosal healing in UC 
 
 
OE-i-scan i-scan 1 
Surface enhancement 
i-scan2 
Tone enhancement 
i-scan 3 
Optical enhancement  
 
Brightness  
 
0 
 
+2 
 
+2 
 
Average -Peak 
 
Ave 
 
Ave 
 
Ave 
 
Blue  
 
0 
 
0 
 
0 
 
Red 
 
0 
 
0 
 
0 
 
Enhancement  
 
Low/+2 
 
Low/+2 
 
Low/+2 
 
Surface Enh. 
 
+5 
 
+5 
 
NA 
 
Tone Enh. 
 
Off 
 
C 
 
NA 
Mayo Endoscopic 
subscore 
0E-iSCAN  
mucosal pattern 
OE-iSCAN  
vascular pattern 
  1 2 3 4 1 2 3 4 
0 10 13 1 - 7 16 1 - 
1 1 - 5 - 1 - 5 - 
2 - 6 - - - 1 5 - 
3 - - 1 4 - - 2 3 
 
OE 
 
Off 
 
Off 
 
Mode1 
                                                                                                    Pattern                            Vessel 
Inflammation/Healing                Detection                       Characterization          Characterization 
 
 
 
 
 
 
 
 
 
 
 
Tables 4 Histological scores 
 
Table 4a. IBD Histological Grading Proposal (ECAP System) 
 
Histopatology  Grade/score 
Extent of inflammation (E)  
            Focal 1   
            Multifocal (patchy) 2 
            Diffuse 3 
Chronicity (C)  
C1.Crypt Architectural Alteration   
            None  0 
            Focal Alteration  1 
            Patchy Distortion (<50%) 2 
            Diffuse Distortion (>50%) 3 
C2.Paneth cell Metaplasia   
            None  0 
            Present  1 
Activity of inflammation (A)  
A1.Surface epithelium   
            Normal 0 
            Reactive changes (mucin 
depletion/villiform) 
1 
            Neutrophilic  infiltration  2 
            Erosion  3 
            Ulceration 4 
A2.Neutrophilic cryptitis  
            None 0 
            >5% 1 
            <50% 2 
            >50% 3 
A3.Crypts Abscess 4 
           None  0 
           Present  1 
A4.Crypts  Destruction  
           None  0 
           Crypt Destruction 1 
A5.Lamina Propria Mononuclear    
      Cellularity 
 
           Normal 0 
           Mild increase 1 
           Moderate increase 2 
           Severe increase 3 
A6.Basal Plasmcytosis   
           None  0 
           Focal  1 
           Diffuse 2 
A7.Lamina Propria Neutrophilic  
      Infiltration 
 
           None 0 
           Rare 1 
           Scattered 2 
           Extensive 3 
Plus/Others(P)  
P1.Lamina Propria  Eosinophilic  
      Infiltration 
 
           None 0 
           Mild 1 
           Moderate 2 
           Severe 3 
P2.Lymphoid Follicle /Aggregates   
           None 0 
           Rare 1 
           Prominent 2 
Total Score  
 
 
Table 4b. Robarts Histologic index score   
 
  
Component 
 
Chronic inflammatory infiltrate  
0=No increase  
1=Mild but unequivocal increase 
2=Moderate increase 
3=Marked increase 
 
Lamina Propria neutrophilis  
0=No increase  
1=Mild but unequivocal increase 
2=Moderate increase 
3=Marked increase 
 
Neutrophils in epithelium  
0=None 
1=<5% crypts involved  
2=<50% crypts involved  
3=>50% crypts involved 
 
Erosion or ulcerations  
0=No erosions ,ulcerations or granulation tissue  
1=Recovering epithelium+adjacent inflamamtion 
1=probable erosion-focally stripped 
2=unequivocal erosion 
3=ulcer or granulation tissue 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4c. New York Mount Sinai scoring system 
                   Score Description 
           0 – inactive colitis 
 
No cryptitis 
           1 – mildly active colitis 
 
Cryptitis in <50% of crypts 
          2- moderately active colitis 
 
Cryptitis in >50% of crypts 
         3 – severely active colitis Ulceration or erosion 
 
 
 
 
Table 5. Spearman's rank correlation coefficient between Mayo and OE-iscan scores and 
Histology 
 
 
Endoscopic 
scores  
Harpaz ECAP RHI P value 
Mayo  
95%CI 
0.55 
(0.32-0.71) 
0.42 
(0.17-0.634) 
0.49 
(0.24-0.67) 
P<0.001 
OE-iscan  
Mucosal 
95%CI 
 
0.61 
(0.41-0.26) 
 
0.71 
(0.54-0.82) 
 
0.61 
(0.4-0.75) 
      
 P<0.001 
OE- iscan  
Vascular 
95%CI 
  
0.62 
(0.41-0.76) 
 
0.65 
(0.45-0.780 
 
0.56 
(0.33-0.72) 
 
P<0.001 
OE-iscan  
Overall 
95%CI 
0.64 
(0.44-0.77) 
0.70 
(0.52-0.81) 
0.61 
(0.-4-0.75) 
P<0.001 
 
 
 
 
 
 
 
 
 
 
Table 6. Sensitivity, Specificity,Accuracy, PPV and NPV of OE-iscan 
 
 OE-iSCAN & WL 
Mayo 
OE-iSCAN       
&ECAP 
OE-iSCAN 
&RHI 
 
 
WL-Mayo 
&ECAP 
WL-Mayo 
&RHI 
Sensitivity ,(%) 
95%CI 
47 
(0.31-0.63) 
78 
(0.63-0.84) 
78.1 
(0.61-0.89) 
36 
(0.24-0.49) 
37.5 
(0.22-0.54) 
 
Specificity,(%) 
95%CI 
 
93.7 
(0.71-0.98) 
 
100 
(0.56-100) 
 
50 
(0.29-0.70) 
 
NaN 
- 
 
83.3 
(0.60-0.94) 
 
Accuracy,(%) 
 
 
62 
 
80 
 
68 
 
36 
 
54 
 
PPV, (%) 
95%CI 
 
94.1 
(73-98.9) 
 
100 
(90-100) 
 
73.5 
(56.8-85.3) 
 
100 
(82.4-100) 
 
80 
(55-93) 
      
NPV,(%) 
95%CI 
45.4 
(29.8-62) 
33 
(15.1-58.2) 
56.2 
(33.1-76.9) 
0 
(0-10.7) 
42,8 
(28-59) 
      
 
